This pooled analysis reports that nivolumab has similar efficacy and safety outcomes in patients with tumors with wild-type or mutant BRAF kinase, regardless of prior BRAF inhibitor or ipilimumab treatment.
This case-control study finds that in patients initiating palliative chemotherapy for cancer, readily available clinical data can predict patient-specific risk of chemotherapy-related hospitalization.
This report of NeoALTTO trial data found that the presence of tumor-infiltrating lymphocytes at diagnosis is an independent, positive, prognostic marker in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer treated with neoadjuvant anti-HER2 agents and chemotherapy.
In a secondary analysis of a phase 3 randomized clinical trial, Aoyama and colleagues investigated the feasibility of stereotactic radiosurgery alone for patients with brain metastases from non–small-cell lung cancer exhibiting different prognoses, finding that whole-brain radiotherapy for patients with a favorable prognosis should be still be considered.
This whole-exome sequencing study found that the majority of advanced, treatment-resistant tumors across tumor types harbor biologically informative genetic alterations.
The data from this study suggest that buccal cells are likely a more appropriate source of tissue than blood to conduct epigenome-wide association studies for smoking-related epithelial cancers.
This observational study found that ADAMTS mutations may contribute to outcomes in ovarian cancer cases without BRCA1 or BRCA2 mutations and may have important clinical implications.
This retrospective analysis of patients with hormone-sensitive prostate cancer found that statin use at the time of initiation of androgen deprivation therapy was associated with a significantly longer time to progression.
Using Global Burden of Disease (GBD) 2013 methodology, the GBD Cancer Collaboration investigators estimate mortality, incidence, years lived with disability, years of life lost, and disability-adjusted life years for 28 cancers in 188 countries by sex from 1990 to 2013.
This narrative review summarizes recent advances in understanding tumor biology and using targeted therapies for patients with metastatic breast cancer.
As tumors are increasingly treated based on their specific molecular profile, imaging biomarkers should become an essential diagnostic tool for selecting appropriate therapies and assessing their response to treatment.
This Viewpoint advocates moving beyond the “War on Cancer” metaphor and proposes priorities in clinical practice, messaging, and research to help guide a successful quality-of-life agenda for patients with cancer and cancer survivors.
This editorial discusses the importance of using global burden of cancer assessments to provide an actionable framework for policy makers to improve cancer care, particularly in low- and middle-income countries, where health resources are limited and competing health demands are great.
Neoadjuvant therapy is explained as cancer treatment given before the main treatment to increase the main treatment’s chances of success
Create a personal account or sign in to: